Lotte Biologics designa a James Park como nuevo CEO para mejorar los esfuerzos de expansión global. Lotte Biologics appoints James Park as new CEO to enhance global expansion efforts.

Lotte Biologics, subsidiaria de Lotte Group, ha nombrado a James Park como su nuevo CEO para impulsar su presencia en el mercado mundial. Lotte Biologics, a subsidiary of Lotte Group, has appointed James Park as its new CEO to boost its global market presence. Park, anteriormente CEO de GC Cell y con experiencia en empresas como Merck y Samsung Biologics, se espera que ayude a la compañía a expandirse a nivel internacional. Park, previously CEO of GC Cell and with experience at companies like Merck and Samsung Biologics, is expected to help the company expand internationally. El nombramiento está a la espera de una junta de accionistas. The appointment is pending a shareholders' meeting.